ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Dutch government has committed $63 million to support the BioMedical Materials program. Set up by Dutch specialty chemicals firm DSM and the University of Maastricht, the five-year program will have a budget of $126 million and will investigate new materials to improve health care for patients suffering from cancer as well as cardiovascular, kidney, and musculoskeletal diseases. Nearly 30 other entities plan to participate in the program, including Dutch academic and medical institutions, the drug company Organon International, medical device maker Medtronic, and clinical chemical analyzer maker FujiFilm Life Science. According to DSM, the program is intended to strengthen the Netherlands' position in biomedical materials by developing new applications, securing intellectual property rights, and generating scientific papers. DSM adds that the program will further its ambition to become a leading player in the biomedical market. The firm currently supplies hydrophilic coatings for catheters and ultra-high-molecular-weight polyethylene fiber for orthopedic implants.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter